Asymmetry Capital Management L.P. Takes $643,000 Position in Antares Pharma, Inc. (ATRS)

Asymmetry Capital Management L.P. acquired a new position in shares of Antares Pharma, Inc. (NASDAQ:ATRS) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 199,655 shares of the specialty pharmaceutical company’s stock, valued at approximately $643,000. Antares Pharma makes up 0.8% of Asymmetry Capital Management L.P.’s portfolio, making the stock its 26th biggest position. Asymmetry Capital Management L.P. owned about 0.13% of Antares Pharma as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alliancebernstein L.P. bought a new position in shares of Antares Pharma during the 2nd quarter worth approximately $119,000. Legal & General Group Plc bought a new position in shares of Antares Pharma during the 2nd quarter worth approximately $120,000. MML Investors Services LLC raised its stake in shares of Antares Pharma by 228.2% during the 2nd quarter. MML Investors Services LLC now owns 43,147 shares of the specialty pharmaceutical company’s stock worth $139,000 after acquiring an additional 30,000 shares in the last quarter. Credit Suisse AG bought a new position in shares of Antares Pharma during the 1st quarter worth approximately $146,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of Antares Pharma during the 2nd quarter worth approximately $174,000. Hedge funds and other institutional investors own 36.77% of the company’s stock.

Antares Pharma, Inc. (ATRS) traded down 4.31% during mid-day trading on Thursday, reaching $3.77. 3,593,167 shares of the company’s stock traded hands. The stock’s 50 day moving average is $3.21 and its 200-day moving average is $3.00. Antares Pharma, Inc. has a 52 week low of $1.41 and a 52 week high of $4.09. The stock’s market capitalization is $589.65 million.

Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The business had revenue of $13.42 million for the quarter, compared to analysts’ expectations of $12.99 million. Antares Pharma had a negative net margin of 34.27% and a negative return on equity of 41.37%. On average, equities analysts anticipate that Antares Pharma, Inc. will post ($0.11) EPS for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/2955732/asymmetry-capital-management-l-p-takes-643000-position-in-antares-pharma-inc-atrs.html.

Several research analysts recently commented on ATRS shares. Vetr upgraded shares of Antares Pharma from a “hold” rating to a “buy” rating and set a $3.30 price objective for the company in a research note on Wednesday, July 5th. Chardan Capital started coverage on shares of Antares Pharma in a research note on Friday, June 23rd. They set a “buy” rating and a $5.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $5.00 price objective on shares of Antares Pharma in a research note on Friday, June 23rd. Finally, Piper Jaffray Companies reiterated a “buy” rating on shares of Antares Pharma in a research note on Friday, September 8th. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Antares Pharma currently has an average rating of “Buy” and an average price target of $4.34.

In other news, Director Leonard S. Jacob sold 230,000 shares of Antares Pharma stock in a transaction on Monday, October 9th. The shares were sold at an average price of $4.05, for a total value of $931,500.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Thomas J. Garrity sold 30,000 shares of Antares Pharma stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $3.50, for a total transaction of $105,000.00. The disclosure for this sale can be found here. Insiders own 11.60% of the company’s stock.

Antares Pharma Profile

Antares Pharma, Inc (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops, manufactures and commercializes therapeutic products using its drug delivery systems. Its subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injector system suitable for branded and generic injectable drugs in unit dose containers, reusable needle-free spring-action injector devices, and disposable multi-use pen injectors for use with cartridges.

Want to see what other hedge funds are holding ATRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Antares Pharma, Inc. (NASDAQ:ATRS).

Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


Leave a Reply

© 2006-2017 Ticker Report. Google+.